(II) BRU124EX (SEQ ID NO: 2)

W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(III) BRU124F1X (SEQ ID NO: 3)

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z

C1 cont'd

(IV) BRU124F3X (SEQ ID NO: 4)

W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-Y-Z

(V) ROD 124E1 (SEQ ID NO: 5)

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(VI) ROD 124EX (SEQ ID NO: 6)

W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(VII) ROD 124C2X (SEQ ID NO: 7)

W-X-Lys-Leu-Lys-Asp-Phe-Arg-

Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Y-Z

(VIII) ROD 124C1X (SEQ ID NO: 8)

W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Y-Z

(IX) ROD 123C3X (SEQ ID NO: 9)

X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-
Z

C1 cont'd

(X) POL2A1 (SEQ ID NO: 10)

W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
Thr-Asp-Ile-Lys-Ile-Ile-Pro-Arg-Arg-Lys-
Ala-Lys-Ile-Ile-Y-Z

(XI) ROD124C5X (SEQ ID NO: 11)

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z

wherein W is either a H of the amino terminal NH_2 group of the polypeptide or an additional amino acid bonded to the amino terminal NH_2 group of the polypeptide, the additional amino acid being selected to facilitate coupling of the

polypeptide to a carrier protein or to a support; X is absent or Cys-Gly-Gly; Y is absent or Cys; and Z is OH or NH_2; and

(b) detecting whether immunospecific binding has occurred between the polypeptide and an antibody component of the body fluid in which an immune complex is formed and in which the detection of the immune complex indicates the presence of antibodies to HIV in the body fluid.

---

12. (Twice amended) A method for determining the presence of antibodies to HIV-1 in a body fluid, comprising:

(a) contacting, under conditions which permit immunospecific binding to form a reaction mixture, the body fluid with a composition containing at least one polypeptide comprising at least one of the following polypeptide sequences:

(II) BRU124EX (SEQ ID NO: 2)

W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(III) BRU124FX1 (SEQ ID NO: 3)

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z

(IV) BRU124F3X (SEQ ID NO: 4)

W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-Y-Z

wherein W is either a H of the amino terminal NH_2 group of the polypeptide or an additional amino acid bonded to the amino terminal NH_2 group of the polypeptide, the additional amino acid being selected to facilitate coupling of the

polypeptide to a carrier protein or to a support; X is absent or Cys-Gly-Gly; Y is absent or Cys; and Z is OH or NH_2; and

(b) detecting whether immunospecific binding has occurred between the polypeptide and an antibody component of the body fluid in which an immune complex is formed and in which the detection of the immune complex indicates the presence of antibodies to HIV in the body fluid.

13. (Amended) A method for determining the presence of antibodies to HIV-2 in a body fluid, comprising:

(a) contacting, under conditions which permit immunospecific binding to form a reaction mixture, the body fluid with a composition containing at least one polypeptide comprising at least six amino acids which come within at least one of the following polypeptide sequences and including epitopes within such sequence:

C 13 cont'd

(V) ROD 124E1 (SEQ ID NO: 5)

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(VI) ROD 124EX (SEQ ID NO: 6)

W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

(VII) ROD 124C2X (SEQ ID NO: 7)

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z

(VIII) ROD 124C1X (SEQ ID NO: 8)

W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z

(IX) ROD 123C3X (SEQ ID NO: 9)

X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-Z

(X) POL2A1 (SEQ ID NO: 10)

W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Ile-Ile-Pro-Arg-Arg-Lys-Ala-Lys-Ile-Ile-Y-Z

(XI) ROD124C5X (SEQ ID NO: 11)

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z

wherein W is either a H of the amino terminal NH_2 group of the polypeptide or an additional amino acid bonded to the amino terminal NH_2 group of the polypeptide, the additional amino acid being selected to facilitate coupling of the polypeptide to a carrier protein or to a support; X is absent or Cys-Gly-Gly; Y is absent or Cys; and Z is OH or NH_2; and